EMG
OMED

Ellington Management Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Ellington Management Group’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-14,900
Closed -$440K – 921
2013
Q4 		$440K Buy
+14,900
New +$273K 0.16% 209

Other funds holding OMED

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Cupps Capital Management Chicago, Illinois $231M AUM 49.73% 1-Year Est. Return

Ellington Management Group's OMED Position: Q1 2014 in Review

Ellington Management Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2014, closing a stake of 14,900 shares — an estimated $440K sold.

Ellington Management Group first reported a position in OMED in Q4 2013 and held it in 1 quarter. The position peaked at $440K in Q4 2013. 55 funds tracked by Wall St. Rank hold OMED as of Q1 2014.

  • Ellington Management Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Ellington Management Group sold 14,900 OncoMed Pharmaceuticals, Inc. shares in Q1 2014, an estimated $440K.
  • Ellington Management Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Ellington Management Group's OncoMed Pharmaceuticals, Inc. position peaked at $440K in Q4 2013.
  • 55 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2014.

Based on Ellington Management Group's 13F filing for Q1 2014, filed 15 May 2014.